Validation of bi-dimensional (2D) and three-dimensional (3D) Fourier Decomposition (FD) as Magnetic Resonance Imaging (MRI) technique to assess lung ventilation and perfusion compared to computed tomography (CT), Hyperpolarised gases (HP-MRI) and Contrast-Enhanced MRI (CE-MRI)
- Conditions
- cystic fibrosis1003868610010613
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 19
CF patients
• Diagnosed with CF with sweat and genetic testing
• Age between 10-18 years
• Scheduled for biennial CT scan
• Willing and capable to perform spirometer controlled chest MRI
• Informed consent
Healthy Volunteers
• Age 10-18 years
• Willing and capable to perform spirometer controlled chest MRI
• Informed consent
Healthy volunteers (MRI standardization)
• Age 18 years and older
• Willing and capable to perform chest MRI
• Informed consent
All
• MRI contraindication (i.e. cardiac pacemaker, metallic implant, hearing aids,
etc.)
• Claustrophobic
• Pregnancy
• Not willing or unable to perform MRI
CF Patients
• Recent (< 1 month) RTE with use of i.v. antibiotics
• Chronic oxygen therapy
• Any other severe comorbidities that could limit imaging
Healthy volunteers
• Recent (< 1 month) history of lung disease (i.e. pneumonia)
• Known history of chronic lung disease (i.e. asthma)
• Known history of congenital lung disease (i.e. bronchopulmonary dysplasia,
tracheomalacia)
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>• Amount of TA quantified on end-expiratory MR images expressed as % TA over<br /><br>the total lung volume<br /><br>• Ventilation defect (VD) on FD-MRI ventilation map expressed as % of total<br /><br>lung volume,<br /><br>• Amount of TA quantified on end-expiratory CT images (CF patients only)<br /><br>expressed as % TA over the total lung volume<br /><br>• PFT outcomes related to TA (FEF75, FEF25-75, and LCI).</p><br>
- Secondary Outcome Measures
Name Time Method